Proteus

 

Pain, an Unsolved Problem

 

        • On January 1, 2001, pain management standards, addressing the assessment and management of pain, went into effect for Joint Commission accredited ambulatory care facilities, critical access hospitals, hospitals, and office-based surgery practices.
        • Inadequate acute pain control is still more the rule than the exception (probably because of the limitations of available analgesic techniques). Fewer than half of postoperative patients receive adequate pain relief. In spite of regulations, over 80% of patients who undergo surgery in the United States report postoperative pain moderate, severe, or extreme. Most of these patients report worse pain control after discharge from hospital.
        • Uncontrolled acute pain has many negative consequences for the patient, for the clinicians managing the patient, and for those who manage the hospital or clinic that deals with acute pain. Poor pain management puts patients at risk, creates needless suffering, and increases costs of care.
        • Anti inflammatory drugs were derivated from aspirin, opiates from morphine and local anesthetics from cocaine.
        • Neosaxitoxin is the first member of a new family of drugs for clinical use, the Site-1 Sodium Channel Blockers, highly specific, long lasting efficient and safe.

 

 

 

Collaboration Agreement

 

        • At the date of 24th day of May, 2010, a Collaboration Agreement was signed by and between PROTEUS S.A. and BOSTON CHILDREN´S HOSPITAL (then known as Children's Hospital Boston).
        • This agreement was designed and focused to collaborate and to conduct research in the field of the clinical use of NEOSAXITOXIN for local anesthesia.
        • The rationale of the agreement was potentiate the assets of both parties, ie: intellectual property, know how, manufacturing facilities and expertise, regulatory expertise, resources for preclinical and clinical investigations.
        • The Principal Investigator and Project Director is Charles Berde, M.D., Ph. D., of the faculty of Boston Children's Hospital, Harvard Medical School.
        • Executive Committee shall use best efforts to comply at all times with the Harvard Medical School Conflict of Interest Policy.

 

 

 

Partnership and Development Program

 

        • At June 12, 2015. Grünenthal Group, an international, family-owned pharmaceutical company, Proteus S.A. and Boston Children’s Hospital announce a collaboration for neosaxitoxin, a novel anesthetic for local anesthesia and post-operative pain management.
        • Following the respective agreement, both Proteus S.A. and Boston Children’s Hospital will remain as key members of the collaboration steering committee.
        • The deal includes up to 85 million USD in upfront and development milestones plus undisclosed sales milestones and royalties.